Literature DB >> 30858110

Reversal of a Treatment-Resistant, Depression-Related Brain State with the Kv7 Channel Opener Retigabine.

Mengyang Feng1, Nicole A Crowley1, Akshilkumar Patel1, Yao Guo1, Sierra E Bugni1, Bernhard Luscher2.   

Abstract

Neuroinflammation is associated with increased vulnerability to diverse psychiatric conditions, including treatment-resistant major depressive disorder (MDD). Here we assessed whether high fat diet (HFD) induced neuroinflammation may be suitable to model a treatment-resistant depressive-like brain state in mice. Male and female mice were fed a HFD for 18 weeks, followed by quantitation of glucose tolerance, inflammatory markers of brain tissue (TNFα, IL-6, IL-1β, Iba-1), neural excitability in the prelimbic cortex (PLC), as well as assessment of emotional reactivity and hedonic behavior in a battery of behavioral tests. In addition, we assessed the behavioral responsiveness of mice to fluoxetine, desipramine, ketamine, and the Kv7 channel opener and anticonvulsant retigabine. HFD exposure led to glucose intolerance and neuroinflammation in male mice, with similar but non-significant trends in females. Neuroinflammation of males was associated with anxious-depressive-like behavior and defects in working memory, along with neural hyperexcitability and increased Ih currents of pyramidal cells in the PLC. The behavioral changes were largely resistant to chronic treatment with fluoxetine and desipramine, as well as ketamine. By contrast, retigabine (also known as ezogabine) normalized neural excitability and Ih currents recorded from slices of HFD-treated animals and significantly ameliorated most of the behavioral impairments, without effects in control diet exposed animals. Thus, treatment resistant depressive-like brain states that are associated with chronic neuroinflammation may involve hyperexcitability of pyramidal neurons and may be effectively treated by retigabine.
Copyright © 2019 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  antidepressant; high fat diet; ketamine; neuroinflammation; neuronal hyperexcitability; obesity

Mesh:

Substances:

Year:  2019        PMID: 30858110      PMCID: PMC6511483          DOI: 10.1016/j.neuroscience.2019.03.003

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  127 in total

Review 1.  The forced swimming test as a model for core and component behavioral effects of antidepressant drugs.

Authors:  I Lucki
Journal:  Behav Pharmacol       Date:  1997-11       Impact factor: 2.293

2.  Neuroinflammation in Alzheimer's disease and major depression.

Authors:  Nikoletta Dobos; Jakob Korf; Paul G M Luiten; Ulrich L M Eisel
Journal:  Biol Psychiatry       Date:  2010-03-15       Impact factor: 13.382

3.  Ketamine as a Prophylactic Against Stress-Induced Depressive-like Behavior.

Authors:  Rebecca A Brachman; Josephine C McGowan; Jennifer N Perusini; Sean C Lim; Thu Ha Pham; Charlene Faye; Alain M Gardier; Indira Mendez-David; Denis J David; René Hen; Christine A Denny
Journal:  Biol Psychiatry       Date:  2015-05-04       Impact factor: 13.382

4.  Ketamine Strengthens CRF-Activated Amygdala Inputs to Basal Dendrites in mPFC Layer V Pyramidal Cells in the Prelimbic but not Infralimbic Subregion, A Key Suppressor of Stress Responses.

Authors:  Rong-Jian Liu; Kristie T Ota; Sophie Dutheil; Ronald S Duman; George K Aghajanian
Journal:  Neuropsychopharmacology       Date:  2015-03-11       Impact factor: 7.853

5.  Effects of chronic ethanol exposure on neuronal function in the prefrontal cortex and extended amygdala.

Authors:  Kristen E Pleil; Emily G Lowery-Gionta; Nicole A Crowley; Chia Li; Catherine A Marcinkiewcz; Jamie H Rose; Nora M McCall; Antoniette M Maldonado-Devincci; A Leslie Morrow; Sara R Jones; Thomas L Kash
Journal:  Neuropharmacology       Date:  2015-07-16       Impact factor: 5.250

6.  Association between repeated unpredictable chronic mild stress (UCMS) procedures with a high fat diet: a model of fluoxetine resistance in mice.

Authors:  Elsa Isingrini; Vincent Camus; Anne-Marie Le Guisquet; Maryse Pingaud; Séverine Devers; Catherine Belzung
Journal:  PLoS One       Date:  2010-04-28       Impact factor: 3.240

7.  Neurogenesis-dependent and -independent effects of fluoxetine in an animal model of anxiety/depression.

Authors:  Denis J David; Benjamin Adam Samuels; Quentin Rainer; Jing-Wen Wang; Douglas Marsteller; Indira Mendez; Michael Drew; Douglas A Craig; Bruno P Guiard; Jean-Philippe Guilloux; Roman P Artymyshyn; Alain M Gardier; Christophe Gerald; Irina A Antonijevic; E David Leonardo; René Hen
Journal:  Neuron       Date:  2009-05-28       Impact factor: 17.173

Review 8.  Depression and sterile inflammation: Essential role of danger associated molecular patterns.

Authors:  Tina C Franklin; Chelsea Xu; Ronald S Duman
Journal:  Brain Behav Immun       Date:  2017-11-02       Impact factor: 7.217

9.  A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers.

Authors:  Charles L Raison; Robin E Rutherford; Bobbi J Woolwine; Chen Shuo; Pamela Schettler; Daniel F Drake; Ebrahim Haroon; Andrew H Miller
Journal:  JAMA Psychiatry       Date:  2013-01       Impact factor: 21.596

Review 10.  Genetic Contributions of Inflammation to Depression.

Authors:  Jacob Barnes; Valeria Mondelli; Carmine M Pariante
Journal:  Neuropsychopharmacology       Date:  2016-08-24       Impact factor: 7.853

View more
  3 in total

1.  Impact of the KCNQ2/3 Channel Opener Ezogabine on Reward Circuit Activity and Clinical Symptoms in Depression: Results From a Randomized Controlled Trial.

Authors:  Sara Costi; Laurel S Morris; Katherine A Kirkwood; Megan Hoch; Morgan Corniquel; Brittany Vo-Le; Tabish Iqbal; Nisha Chadha; Diego A Pizzagalli; Alexis Whitton; Laura Bevilacqua; Manish K Jha; Stefan Ursu; Alan C Swann; Katherine A Collins; Ramiro Salas; Emilia Bagiella; Michael K Parides; Emily R Stern; Dan V Iosifescu; Ming-Hu Han; Sanjay J Mathew; James W Murrough
Journal:  Am J Psychiatry       Date:  2021-03-03       Impact factor: 18.112

Review 2.  Chemical modulation of Kv7 potassium channels.

Authors:  Matteo Borgini; Pravat Mondal; Ruiting Liu; Peter Wipf
Journal:  RSC Med Chem       Date:  2021-01-14

3.  Kv7 Channels and Excitability Disorders.

Authors:  Frederick Jones; Nikita Gamper; Haixia Gao
Journal:  Handb Exp Pharmacol       Date:  2021
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.